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Clinical Implications, Risk Factors and Mortality Following 
Community-onset Bacteremia Caused by Extended-spectrum 
b-lactamase (ESBL) and non-ESBL Producing Escherichia coli
Chia-Jung Hsieh, Yea-Huei Shen, Kao-Pin Hwang*
Division of Infectious Disease, Department of Pediatrics, Chang Gung Memorial Hospital, Kaohsiung Medical Center and 
 Chang Gung University College of Medicine, Kaohsiung, Taiwan.
BACKGROUND/PURPOSE: Infections caused by extended-spectrum β-lactamase (ESBL)-producing 
bacteria have become a serious clinical concern worldwide. The occurrence of ESBLs in Taiwan has been 
well-documented and is reviewed in recent publications. However, studies comparing community-onset 
bacteremia caused by ESBL- and non-ESBL-producing Escherichia coli are limited.
METHODS: We retrospectively reviewed the medical records of patients with E. coli bacteremia who vis-
ited the emergency department of Kaohsiung Chang Gung Memorial Hospital from January 2005 to 
December 2006. Clinical data were collected to compare the clinical features of patients with ESBL-
producing E. coli with those of patients with non-ESBL-producers and to identify the risk factors associ-
ated with ESBL-producing E. coli bacteremia.
RESULTS: There were 404 episodes of community-onset E. coli bacteremia. The overall 30-day mortality 
rate was 11.4% (46/404) and the mortality rate of healthcare-associated infections was significantly 
higher than that of community-acquired infections [4/13 (30.8%) vs. 42/391 (10.7%); p = 0.049] Non-
urinary focus was independently associated with an increased risk of fatality [47/178 (26.4%) vs. 4/226 
(1.8%); p < 0.001]. The frequency of ESBL producers was 4.7% (19/404). Of these, four (21.1%) were associ-
ated with a long-term care facility. Significant risk factors associated with ESBL-producing E. coli bac-
teremia included recent antibiotic exposure (within 30 days) and urinary catheter placement. Although 
the trend was towards higher mortality in patients with ESBL-producing E. coli bacteremia, the difference 
did not reach statistical significance compared with the mortality of patients with non-ESBL E. coli 
bacteremia.
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CONCLUSION: Fewer than 5% of community-onset E. coli bacteremia episodes in Southern Taiwan were 
due to ESBL-producers. Prior antibiotic use within 30 days and urinary catheter placement were inde-
pendently associated with ESBL-producing E. coli bacteremia.
KEYWORDS: bacteremia, community-onset, Escherichia coli, extended-spectrum β-lactamases, risk factors
Methods
Subjects
This retrospective study was conducted at Chang 
Gung Memorial Hospital, Kaohsiung, which is a 2,600-
bed medical center facility located in Southern Taiwan, 
providing both primary and tertiary referral care. It 
receives more than 100,000 emergency room (ER) visits 
per year.
Patients were included if their blood cultures were 
drawn in the ER immediately prior to admission and 
if the culture results were found to be positive. Patients 
who had been admitted on a prior occasion within the 
preceding 30 days were excluded. We reviewed the medical 
records of 1,200 patients from January 2005 to December 
2006. Demographic characteristics, underlying diseases, 
source of specimen (blood, urine, pus, and others), anti-
microbial regimen, any antimicrobial therapy adminis-
tered in the 30 days prior to the onset of bacteremia, 
laboratory data (e.g. leukocyte and platelet counts) and 
clinical outcome (e.g. length of hospitalization, mortality) 
were retrospectively collected for each patient.
Microbiological testing
Bacterial susceptibility to antimicrobial agents was deter-
mined according to criteria of the National Committee 
for Clinical Laboratory Standards.10 ESBL-producing 
E. coli was suspected if the disk-diffusion susceptibility test 
showed the inhibition zone of ceftriaxone was ≤ 25 mm 
or ceftazidime ≤ 22 mm. These isolates were subjected to 
cefotaxime (30 μg) cefotaxime/clavulanate (30/10 μg) and 
ceftazidime (30 μg) ceftazidime/clavulanate (30/10 μg) 
disk testing. ESBL production was evidenced if an in-
crease of ≥ 5 mm in the diameter of the inhibition zone 
was found when clavulanate was combined with either 
Introduction
Extended-spectrum β-lactamases (ESBLs) are a hetero-
geneous group of enzymes responsible for the resistance 
of enterobacteria to extended-spectrum β-lactam anti-
biotics.1 ESBL were first identified in Germany in 1983,2 
and many reports of ESBLs quickly followed in the 
United States. The types of antimicrobial resistance per-
taining to ESBLs have been recognized worldwide in 
the last 20 years. The majority of persons infected with 
ESBL-producing microorganisms have been exposed 
to hospital intensive care units.3,4 Recent data have 
suggested that ESBL-producing Enterobacteriaceae are 
prevalent in community-based settings.5–7 Unlike the no-
socomial multidrug resistant organisms, ESBL-producing 
Escherichia coli are frequently community-onset, particu-
larly those with the worldwide-spread of CTX-M-type 
ESBLs. Furthermore, foreign travel may be a major risk 
factor for developing community-onset ESBL-producing 
E. coli infections.8
As is the case with ESBL-producing Klebsiella pneumo-
niae, treatment with cephalosporins or fluoroquinolones 
for bloodstream infections caused by ESBL-producing 
E. coli is associated with a poorer prognosis than carbap-
enem therapy.9 As the frequency of bacteremia caused by 
ESBL-producing E. coli is increasing, carbapenem use is 
rising, which may contribute to the spread of carbapenem 
resistance. As a result, ESBL-producing E. coli is an emerg-
ing and worrying.
The goal of the study was to evaluate the prevalence, 
clinical features and risk factors of community-onset 
ESBL-producing E. coli bacteremia in Southern Taiwan; 
thus we retrospectively studied all available community-
onset bloodstream infections caused by E. coli from 
January 2005 to December 2006.
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cefotaxime or ceftazidime. The reference strains used were 
E. coli ATCC 25922 and K. pneumoniae ATCC 700603.
Definitions
All variable definitions were established prior to data col-
lection. Bacteremia was defined as the finding of organisms 
in a blood culture specimen. Community-onset bactere-
mia was defined as a positive blood culture taken on, or 
within, 48 hours of admission. These patients, who had 
been hospitalized in the month prior to admission and 
had been transferred from another hospital, were defined 
as having a nosocomial infection. Antimicrobial therapy 
was defined as inappropriate when an active antimicro-
bial agent (as determined by in vitro susceptibility testing) 
at the usual recommended dosage had not been adminis-
tered during the first 48 hours. Episodes of community-
onset bacteremia were further classified as long term care 
facility-associated infections if the patient had been resi-
dent in a nursing home or long-term care facility. All 
other cases of community-onset bacteremia were classified 
as community-acquired infections. Length of hospital stay 
was calculated as the time from the onset of bacteremia to 
discharge home or transfer to a rehabilitation ward.
Statistical analysis
Data analysis was performed using SPSS version 10.0 
(SPSS Inc., Chicago, IL, USA). Categorical variables were 
compared using χ2 test or Fisher’s exact test, as appropriate. 
Continuous variables were compared using the Student’s 
t test. All p values were two-tailed; a p value < 0.05 was con-
sidered statistically significant. Odd ratios (OR) and 95% 
confidence intervals (CI) were calculated for the significant 
factors.
Results
We collected 50 samples per month for 2 years, all with a 
positive blood culture on admission to, or within 48 hours 
of admission to the ER. The total number was 1,200. 
E. coli and K. pneumoniae accounted for 37.5% and 22.9%, 
respectively. Data from 450 patients with E. coli bactere-
mia was collected but five patients were not enrolled owing 
to incomplete medical records. Forty-one patients with 
nosocomial bloodstream infections were excluded, leaving 
404 patients with community-onset E. coli bacteremia.
The ESBL-producing strains included 4.7% (19/404) 
E. coli and 10.4% (26/249) K. pneumoniae. There was no ap-
parent clustering of the case patients in terms of their geo-
graphical distribution. However, ESBL-producing E. coli 
bacteremia occurred mostly in August (5/32, 15.6%) and 
May (4/27, 14.8%).
The demographic and clinical characteristics of the 
patients with community-onset bacteremia caused by 
E. coli are shown in Table 1. In general, there were no sta-
tistical differences in the presumed origin of bacteremia 
between non-ESBL- and ESBL-producing E. coli: urinary 
tract infection (UTI; 55.6% vs. 63.2%), biliary tract infec-
tion (19.5% vs. 10.5%), respiratory tract infection (3.1% vs. 
5.3%), and primary bloodstream infection (18.7% vs. 5.3%). 
How ever, soft tissue infection was caused more frequently 
by ESBL-producing strains than non-ESBL strains (10.5% 
vs. 0.5%; p = 0.01).
The overall mean length of hospital stay was 13.4 ± 
14.0 days (range, 0–120 days). The overall 30-day mortal-
ity rate was 11.4%. In addition, there was no statistical 
significance between 30-day mortality for ESBL- and non-
ESBL-producing E. coli (21.1% vs. 10.9%), as shown in 
Table 2. The mean length of hospital stay for the 30-day 
mortality patients with ESBL- and non-ESBL producing 
E. coli were 15.5 ± 8.5 days and 6.1 ± 6.9 days, respectively 
(p < 0.05). It may be that the length of hospital stay was 
longer for patients with ESBL-producing E. coli bactere-
mia, leading to an overestimation.
We limited our analysis of antibiotic use to the 30 days 
prior to the onset of bacteremia; 46 patients received anti-
biotics according to their medical records. There was an 
association between ESBL production and prior antibi-
otic use (ESBL vs. non-ESBL group, 27.8% vs. 10.8%, re-
spectively; p = 0.044). The other significant risk factors for 
ESBL production were residence in a long-term care facil-
ity and insertion of a Foley catheter (Table 1).
Of 19 episodes of ESBL-producing E. coli bacteremia, 
four (21.1%) were associated with a long-term care facility, 
which was significantly higher than that of the non-
ESBL-producing strains [9/385 (2.3%); p < 0.05]. There 
was no statistical significance in the overall median length 
of hospital stay for the 13 patient’s resident in a long-
term care facility compared with the 391 patients with 
community-acquired infections (12.9 ± 10.7 days vs. 13.4 ± 
12.1 days; data not shown). However, the 30-day mortality 
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Table 1. Demographic characteristics and potential risk factors of patients with community-onset bacteremia caused by non-
extended-spectrum beta-lactamase and extended-spectrum beta-lactamase-producing Escherichia colia
Characteristics Total (n = 404) Non-ESBL (n = 385) ESBL (n = 19) p
Age 61.5 ± 18.3 61.3 ± 18.6 66.1 ± 11.0 0.080
 Range 0–93 0–93 37–82 
 ≤ 50 83 (20.5) 82 (21.3) 1 (5.3)  0.140
 > 50 321 (79.5) 303 (78.7) 18 (94.7) 
Sex    0.093
 Male 168 (41.6) 164 (42.6) 4 (21.1) 
 Female 236 (58.4) 221 (57.4) 15 (78.9) 
Long-term care facility 13 (3.2) 9 (2.3) 4 (21.1) 0.002
Comorbid condition    
 Malignancy 94 (23.3) 89 (23.1) 5 (26.3) 0.780
 Diabetes mellitus 147 (36.4) 139 (36.1) 8 (42.1) 0.600
 Hypertension 147 (36.4) 140 (36.4) 7 (36.8) 0.970
 BPH 33 (8.2) 33 (8.6) 0 (0) 0.390
 Pancreatic and/or hepatic disease 111 (27.5) 107 (27.8) 4 (21.1) 0.520
 Renal disease 77 (19.1) 72 (18.7) 5 (26.3) 0.390
 Heart disease 53 (13.1) 49 (12.7) 4 (21.1) 0.290
 Stroke 56 (13.9) 51 (13.2) 5 (26.3) 0.160
Primary infection site    
 Urinary tract infection 226 (55.9) 214 (55.6) 12 (63.2) 0.640
 Biliary tract infection 77 (19.1) 75 (19.5) 2 (10.5) 0.550
 Sepsis 73 (18.1) 72 (18.7) 1 (5.3) 0.220
 Lung (pneumonia) 13 (3.2) 12 (3.1) 1 (5.3) 0.470
 Cellulitis 4 (1.0) 2 (0.5) 2 (10.5) 0.010
Clinical presentation   
 Fever 328 (81.2) 312 (81.0) 16 (84.2) 1.000
 Neutropenia < 1.2 × 109/Lb 10 (2.5) 9 (2.4) 1 (5.3) 0.390
 Band % > 15b 9 (2.3) 8 (2.1) 1 (5.3) 0.360
 Foley insertion 18 (4.5) 14 (3.6) 4 (21.1) 0.007
 Prior use of antibiotics within 30 dc 46 (11.4) 41 (10.8) 5 (27.8) 0.044
aData presented as mean ± standard deviation or n (%); bOnly 400 results showed absolute neutrophil counts and band form count; conly 399 
cases had medical records showing that antibiotics were used within the preceding 30 days. ESBL = extended-spectrum β-lactamase; 
BPH = benign prostatic hyperplasia.
of patients from long-term care facilities was significantly 
higher than that of patients with community-acquired in-
fections (33.3% vs. 10.7%; p < 0.05). Furthermore, when we 
analyzed the association between the primary site of in-
fection and mortality, non-urinary focus (47/178, 26.4%; 
p < 0.001) was independently associated with an increased 
risk of death.
In this study, 67 episodes of E. coli bacteremia were 
combined with other pathogens, but there were no statis-
tical difference between the proportion of those with or 
without ESBL [62/385 (16.1%) vs. 5/19 (26.3%); p = 0.22]. 
However, we found that, among UTIs, ESBL E. coli bac-
teremia seemed to be accompanied by other pathogens 
compared with non-ESBL E. coli bacteremia (p < 0.05; 
Table 3).
The antibiograms of the 404 isolates with non-ESBL 
and ESBL-producing E. coli are shown in the Figure. 
Imipenem was the only antibiotic agent to which all iso-
lates were susceptible. In our study, the susceptibility of 
E. coli to gentamicin, trimethoprim/sulfamethoxazole and 
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piperacillin was poor, even against non-ESBL-producers. 
Iso lates of ESBL-producing E. coli were more resistant to 
gentamicin [11/19 (57.9%) vs. 87/385 (22.6%); p < 0.05] 
and ciprofloxacin [10/19 (52.6%) vs. 54/385 (14.0%); p < 
0.05] than isolates of non-ESBL-producing E. coli, as shown 
in Table 4. Among non-ESBL E. coli bacteremia, resistance 
to aztreonam (3.38%), ceftazidime (5.71%), ceftriaxone 
(5.97%) and cefuroxime (7.01%) was an independent risk 
factor for mortality (p < 0.05; Table 5).
Discussion
Infections caused by ESBL-producing bacteria have be-
come a serious clinical concern worldwide. The occurrence 
of ESBLs in Taiwan has been well-documented and is re-
viewed in recent publications.11 Relatively high incidence 
figures for ESBL phenotypes were reported for three cen-
ters in Northern Taiwan, contributing to the 1998–2002 
SENTRY programs, with overall rates of ESBL production 
of 13.5% for K. pneumoniae and 5.6% for E. coli.12 However, 
our study was undertaken to evaluate the risk factors and 
the prevalence of ESBL-producing E. coli bacteremia at the 
community level, to distinguish the clinical manifestations 
of E. coli bacteremia with and without ESBL, and to detect 
the antimicrobial resistance patterns in Southern Taiwan.
In this study, 4.7% (19/404) of cases had ESBL-
producing E. coli bacteremia; a similar frequency to that 
reported by Kang et al.13 The prevalence of ESBL-
producing E. coli bacteremia was higher in patients who 
acquired bacteremia while in a long term care facility 
than in those who acquired it in the community (30.8% vs. 
3.8%; p < 0.05).
Previous studies have recognized potential risk factors 
for community-onset ESBL-producing E. coli bacteremia, 
including diabetes mellitus, previous fluoroquinolone 
use, recurrent UTIs, previous hospital admission, older 
Table 2. Differences of outcome between non-extended-spectrum β-lactamase and extended-spectrum β-lactamase-producing 
Escherichia coli bacteremiaa
Outcomes Total (n = 404) Non-ESBL (n = 385) ESBL (n = 19) p
Crude mortality 51 (12.6) 47 (12.2) 4 (21.1)    0.28
 3-day mortality 25 (6.2) 24 (6.2) 1 (5.3) NS
 15-day mortality 39 (9.7) 38 (9.9) 1 (5.3) NS
 Hospital stay (d) 13.4 ± 14.0 13.1 ± 13.0 (0–96) 21.0 ± 27.1 (1–120)    0.22
30-day mortality 47 (11.4) 42 (10.9) 4 (21.1)    0.25
 Hospital stay (d) 6.7 ± 7.4 6.1 ± 6.9 (0–27) 15.5 ± 8.5 (3–22) < 0.05
aData presented as n (%) or mean ± standard deviation. ESBL = extended-spectrum β-lactamase; E.coli = Escherichia coli; NS = not significant.
Table 3. Frequency of Escherichia coli bacteremia with or without extended-spectrum β-lactamase combined with other pathogens 
in different primary infection site
 Total (n = 404)  Non-ESBL (n = 385)  ESBL (n = 19)  p
Number of case 67 (16.7) 62 (16.1) 5 (26.3) 0.220
Primary infection site
 Urinary tract infection 14/226 (6.2) 10/214 (4.7) 4/12 (33.3) 0.004
 Biliary tract infection 26/77 (33.8) 26 (34.7) 0 (0) 0.550
 Sepsis 19/73 (26) 19 (26.4) 0 (0) 1.000
 Lung 5/13 (38.5) 5/12 (92.3) 0 (0) 1.000
 Othersb 2   
aData presented as n (%); bone case of cellulitis caused by non-ESBL E. coli; one case of pelvic inflammatory disease caused by ESBL-producing 
E. coli. ESBL = extended-spectrum β-lactamase; E. coli = Escherichia coli.
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age, and male sex.14 Our present study revealed residence 
in a long-term care facility, cellulitis and Foley catheter in-
sertion were significantly risk for ESBL production in pa-
tients with community-onset E. coli bacteremia. In terms 
of cellulitis, one site was over the left foot and another was 
a peritoneal abscess. Although Gram-negative cellulitis is 
not particularly common, there are several case reports 
published in the literature.15,16 To our knowledge, there 
are no reports of cellulitis caused by ESBL-producing 
E. coli.
Pedersen et al demonstrated that previous antibiotic 
prescriptions were strongly associated with antimicrobial 
resistance in community-onset bacteremia, especially with 
E. coli.17 In addition, recent studies show that previous use 
of oxyimino-β-lactams or fluoroquinolones is a risk fac-
tor for ESBL-producing isolates in patients with bac-
teremia caused by E. coli.18,19 We limited our analysis of 
antibiotic use to 30 days before the onset of bacteremia 
and we only assessed the association between ESBL-
producing E. coli and previous antibiotic use (p = 0.044).
A
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Figure. Antimicrobial susceptibility of extended and non-extended spectrum β-lactamase producing Escherichia coli at Chang-Gung 
Memorial Hospital, Kaohsiung. Sensitivity of E. coli and ESBL-E. coli to antimicrobial drugs was as follows: Imipenem = 100%; cipro-
floxacin = 86% vs. 47.7%; gentamicin = 77.4% vs. 42.1%; amikacin = 98.7% vs. 84.2%. ESBL = extended-spectrum beta-lactamase; TMP-
SMX = trimethoprim-sulfamethoxazole.
Table 4. Comparison of the antimicrobial susceptibility of 
non-extended and extended-spectrum β-lactamase-producing 
Escherichia colia
Antibiotics Non-ESBL (n = 385) ESBL (n = 19) p
Ciprofloxacin   < 0.001
 R 54 (14.0) 10 (52.6)
 S 331 (86.0) 9 (47.7)
Gentamicin   0.001
 I 4 (1.0) 1 (5.3)
 R 83 (21.6) 10 (52.6)
 S 298 (77.4) 8 (42.1)
Amikacin   < 0.001
 I 2 (0.5) 0 (0)
 R 3 (0.8) 3 (15.8)
 S 380 (98.7) 16 (84.2)
Imipenem
 S 385 (100) 19 (100)
aData presented as n (%). ESBL = Extended-spectrum β-lactamase; 
E. coli = Escherichia coli.
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With regard to the clinical impact of ESBL-producing 
E. coli bacteremia, a number of studies observed that pa-
tients with infection caused by ESBL-producing E. coli 
tended to have poorer outcomes, longer length of stay, 
higher mortality, and excess hospital charges than those 
caused by non-ESBL producers.20,21 In our study, there 
was no statistical difference in the 30-day mortality rate 
and of length of hospital stay for non-ESBL and ESBL-
producing E. coli bacteremia. The question of whether 
ESBL-production significantly increases the risk of death 
remains unresolved.22 Compared with other studies,19,20 
our crude mortality rate was lower, but the length of hos-
pital stay was longer. Nevertheless, long-term care facility-
associated infections had a higher 30-day mortality rate 
than community-acquired bloodstream infections. The mor-
tality rate between long-term care facility and community-
acquired E. coli bacteremia seems be similar to that in a 
previous report.23
Interestingly, in our study, mortality was higher if the 
non-ESBL producing E. coli was resistant to oxyimino-
β-lactams (Table 5). The reason for this may be that 
our empiric therapy for E. coli infection was cepha-
losporins, with or without aminoglycosides, meaning 
that the inappropriate antibiotic was used initially. The 
antibiograms in our study showed that imipenem was the 
only antibiotic agent to which all isolates were suscepti-
ble. Of the ESBL producers, resistance to gentamicin 
(11/19, 57.9%) and amikacin (3/19, 15.8%) was higher 
than in previous reports.18,21 However, resistance to cipro-
floxacin (10/19, 52.6%) was lower than in a previous 
study.21 In cases of non-ESBL E. coli bacteremia, resistance 
to amoxicillin/clavulanate, ciprofloxacin, trimethoprim/
sulfamethoxazole, gentamicin, and amikacin was higher 
than in other studies.17 Therefore, resistance rates need to 
be kept in mind when selecting antibiotics to treat E. coli 
infections.
As to the source of the bloodstream infections, more 
than half of the patients had UTI. We found that non-
urinary tract focus was associated with an increasing 
risk of death, regardless of whether non-ESBL or ESBL-
producing E. coli was the pathogen; this is similar to a pre-
vious study.24
Notably, in our study, 67 patients (16.6%) had poly-
microbial bloodstream infections, and we found that UTI 
caused by ESBL-producing E. coli were frequently present 
alongside polymicrobial bloodstream infections. In other 
words, if a UTI is caused by ESBL-producing E coli, other 
pathogens must also be considered, and broad spectrum 
antibiotics should be used. To our knowledge, there are 
few reports about the association between polymicrobial 
bloodstream infections, primary site of infection and the 
ESBL producer, and more research is needed.
The main limitation of our study is that the small 
sample size might not allow for the evaluation of risk 
Table 5. Difference between drug susceptibility of Escherichia coli and mortality rate (n = 385)
Drug Alive Dead p  Odds ratio 95% confidence interval
Aztreonam     (0.064, 0.651)
 S 330 42 0.013 0.204 
 R 8 5   
Ceftazidime     (0.126, 0.916)
 S 322 41 0.039 0.340 
 R 16 6   
Ceftriaxone     (0.110, 0.732)
 S 322 40 0.014 0.284 
 R 16 7   
Cefuroxime     (0.143, 0.903)
 S 318 40 0.034 0.359 
 R 20 7
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factors for some subgroups of patients, and might have 
been insufficient to detect other relevant risk factors for 
ESBL-producing E. coli infections. In addition, as this study 
was of a retrospective nature, the possibility of the limita-
tion in precluding accurate comparisons should be kept 
in mind. In fact, some selection bias may have occurred 
during the review process. Since the study was carried out 
in a tertiary hospital, many of our patients had serious 
underlying illness, including neoplastic diseases and 
chronic liver disease. Thus the results may not be applica-
ble to other institutions.
In conclusion, this study showed that the prevalence 
of ESBL-producing E. coli in community-onset bacteremia 
of Southern Taiwan was 4.7%. Independent risk factors 
for ESBL-producing E. coli were residence in a long term 
care facility, urinary catheterization, possible previous an-
tibiotic use and older age. In vitro, ESBL-producing E. coli 
were susceptible to flomoxef and amikacin, but whether 
these antibiotics are a reliable alternative to carbapenems 
in clinical practice is a question that needs further study. 
Therefore, the physician should be aware of such high-
risk patients and target the initial appropriate empirical 
antimicrobial therapy to minimize the mortality of those 
with community-onset bloodstream infections due to 
ESBL-producing E. coli.
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